437 results
8-K
EX-99.1
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
tax rates were 11.6% and 13.5%, respectively, and benefited from the resolution of an uncertain tax matter and higher non-cash tax benefits from … , filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners’ products and investigational therapies
8-K
EX-99.1
ndbe97w0y 8g
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
z4wjo
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.2
1oc8k
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.1
59zgj2923fx3i
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
jo0wq35avtlz
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
ce4ka4
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-99.1
t0oajle6zdp anp8
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-10.1
ssnk2 6u9oed6
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
9tl0qbcnoawrp7dte62j
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
EX-2.1
zaqox7y3j7gdsyig1xmf
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
yeg3i13n02z9u7 z9o
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
0cd p8ch1
31 Jul 23
Entry into a Material Definitive Agreement
7:00am